Beneficial effects of Amiloride on progression of Chronic Kidney Disease: A-CKD

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500692-31-00

Enrollment

Registered

2023-11-10

Start date

2024-10-10

Completion date

Unknown

Last updated

2025-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease (CKD)

Brief summary

Urine C3a, Urine soluble C5-9-sTCC/MAC, KIM-1, NGAL

Detailed description

Urine albumin/creatinine ratio, Urine protein/creatinine ratio, Blood pressure

Interventions

DRUGMODAMIDE 5 mg

DRUGcomprimé

DRUGPLACEBO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Urine C3a, Urine soluble C5-9-sTCC/MAC, KIM-1, NGAL	—

Secondary

Measure	Time frame
Urine albumin/creatinine ratio, Urine protein/creatinine ratio, Blood pressure	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026